Cipla to market it pan-India
Roche India and Cipla announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients.THIS CAN BE YOUR ADVERTISEMENT
Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centres. The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.
“Roche is deeply committed to supporting the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” said V Simpson Emmanuel, MD and CEO, Roche Pharma India.
Commenting on the launch, Umang Vohra, MD and Global CEO Cipla said, “We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country”.
The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk* of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days.
